Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$472.35 USD

472.35
432,975

+3.17 (0.68%)

Updated Sep 6, 2024 04:00 PM ET

After-Market: $470.94 -1.41 (-0.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 249)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

IDEXX (IDXX) Suffers From Macro Headwinds, Cost Constraints

by Zacks Equity Research

The strengthening of the rate of exchange for the U.S. dollar relative to other currencies has a negative impact on IDEXX's (IDXX) revenues.

IDEXX (IDXX) Q2 Earnings Surpass Estimates, 2022 View Down

by Zacks Equity Research

IDEXX's (IDXX) Q2 top-line benefits from strong sales at the CAG and Water businesses.

Idexx Laboratories (IDXX) Surpasses Q2 Earnings Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of 1.30% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Quotient (QTNT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OCPNY or IDXX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

OCPNY vs. IDXX: Which Stock Is the Better Value Option?

Urmimala Biswas headshot

3 MedTech Stocks That are Likely to Beat This Earnings Season

by Urmimala Biswas

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how STE, TMO and IDXX are poised ahead of their earnings releases.

    IDEXX (IDXX) to Report Q2 Earnings: What's in the Cards?

    by Zacks Equity Research

    IDEXX's (IDXX) Q2 performance will likely benefit from strong sales from the CAG Diagnostics and Water businesses.

    Idexx Laboratories (IDXX) Expected to Beat Earnings Estimates: Should You Buy?

    by Zacks Equity Research

    Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Can Idexx (IDXX) Keep the Earnings Surprise Streak Alive?

    by Zacks Equity Research

    Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?

    by Zacks Equity Research

    Sector ETF report for PTH

    Are Options Traders Betting on a Big Move in IDEXX Laboratories (IDXX) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to IDEXX Laboratories (IDXX) stock based on the movements in the options market lately.

    Steris (STE) Up 1.5% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Why Is Idexx (IDXX) Up 0.3% Since Last Earnings Report?

    by Zacks Equity Research

    Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    IDEXX's (IDXX) Soft LPD Sales, Margin Pressure Concern

    by Zacks Equity Research

    Distributor purchasing dynamics have an impact on IDEXX's (IDXX) CAG segment product sales.

    Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?

    by Zacks Equity Research

    Style Box ETF report for IWP

    IDEXX (IDXX) Q1 Earnings Surpass Estimates, Margins Down

    by Zacks Equity Research

    Strong sales at the CAG and Water businesses drove IDEXX's (IDXX) first-quarter 2022 revenues.

    Idexx Laboratories (IDXX) Q1 Earnings Beat Estimates

    by Zacks Equity Research

    Idexx (IDXX) delivered earnings and revenue surprises of 0.89% and 0.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Urmimala Biswas headshot

    MedTech Stocks' Q1 Earnings Due on May 4: CRL, IDXX & NUVA

    by Urmimala Biswas

    MedTech companies' results are likely to reflect a rebound in the base business. Let's see how CRL, IDXX and NUVA fare this time.

    Earnings Preview: Idexx Laboratories (IDXX) Q1 Earnings Expected to Decline

    by Zacks Equity Research

    Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    IDEXX (IDXX) to Report Q1 Earnings: What's in the Cards?

    by Zacks Equity Research

    Strength in CAG Diagnostics and Water businesses is likely to have contributed to IDEXX's (IDXX) top line in the first quarter.

    Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?

    by Zacks Equity Research

    Sector ETF report for PTH

    IDEXX (IDXX) CAG Sales Gain Traction, FX Headwind Persists

    by Zacks Equity Research

    IDEXX (IDXX) has been witnessing continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.

    Accuray's (ARAY) CyberKnife Effective for Relief From TN Pain

    by Zacks Equity Research

    Latest data indicates that Accuray's (ARAY) CyberKnife System is effective in providing long-lasting pain relief to patients suffering from TN.

    3 Reasons to Retain Accuray (ARAY) Stock in Your Portfolio

    by Zacks Equity Research

    Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.

    Masimo (MASI) Reports Preliminary Q1 Results, Reiterates '22 View

    by Zacks Equity Research

    Masimo's (MASI) first-quarter 2022 results are likely to have been dampened by supply chain headwinds.